|Articles|February 9, 2015
New Drug Combination Promises SVR 6 in hepatitis C
Achillon's NS5A inhibitor is being evaluated with Gilead's Sovaldi in treatment-naive hepatitis C patients.
Advertisement
Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in 6 weeks, the shortest duration and highest response achieved by any 2-drug treatment
Achillion's shares rose as much as 19 percent to $12.85 on Monday on investor's hopes that an all-Achillion combination could be as effective as Gilead's and AbbVie Inc's current therapies.
The estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent years, with several companies including Gilead, AbbVie and Merck & Co Inc working on faster, more potent ways to cure the liver-destroying virus, which affects more than 170 million globally.
Link to the news on Reuters:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
